Navigation Links
Study Shows Novartis Drug Afinitor® Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients
Date:12/9/2010

sease progression seen in the everolimus plus tamoxifen treatment arm reinforces the potential benefit of inhibiting mTOR to help overcome endocrine therapy resistance," said Thomas Bachelot, MD, from Centre Leon Berard in Lyon, France, and principal investigator of the study. "Based on these results, additional studies will evaluate the combination of everolimus with hormonal therapies as a second-line treatment for patients with HR+/HER2- metastatic breast cancer."

Breast cancer patients with advanced disease who become resistant to hormonal therapies have limited treatment options(2). Prior to these study findings, Novartis Pharmaceuticals Corporation ("Novartis") initiated a Phase III trial program called BOLERO (Breast cancer trials of OraL EveROlimus), which is the largest international Phase III clinical trial program to study an mTOR inhibitor in patients with locally advanced or metastatic breast cancer(4,5,6).

"These results are encouraging because if everolimus is approved for this indication, it could offer physicians a new strategy to treat patients with metastatic breast cancer whose disease progresses or becomes resistant to traditional hormonal therapies," said Herve Hoppenot, President, Novartis Oncology. "Novartis has a Phase III study underway researching the potential of everolimus for this patient population, which currently has limited treatment options."

For more information about the BOLERO trials, healthcare professionals can visit www.clinicaltrials.gov. Study Details This randomized Phase II trial evaluated the efficacy and safety of everolimus in 111 patients with HR+/HER2- metastatic breast cancer with prior exposure to AI treatment (in adjuvant and/or metastatic setting). Patients were randomized 1:1 to receive everolimus plus tamoxifen (10 mg/day plus 20 mg/day, respectively) [N=54] or tamoxifen alone (20 mg/day) [N=57]. The primary endpoint was clinical benefit rate, d
'/>"/>

SOURCE Novartis
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... May 20, 2013  Echo Pharma Acquisition Limited ("Royalty ... Irish Takeover Rules (the "Announcement"), a firm intention to ... ELN ) to $12.50 per share in cash.  ... not conditional on due diligence.  The $1.00 per share ... reserved the right to waive down the Acceptance Threshold ...
(Date:5/20/2013)...  Atlantic Pharmaceuticals, Inc., a specialty pharmaceutical company ... technology to deter prescription drug abuse today announced ... Soscia , has been chosen as a ... Health-Care Heroes Awards. The awards are presented annually ... individuals and organizations demonstrating excellence and deserving recognition ...
(Date:5/20/2013)... -- Rhythm announced today the presentation of results from a ... symptoms among diabetic patients in the U.S. than previously ... with both type 1 and type 2 diabetes, but ... more common type 2 disease. ... of Medicine at Harvard Medical School and Director of ...
Breaking Medicine Technology:Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 2Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 3Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 4Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 5Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 6Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 7Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 8Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 9Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 10Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 11Atlantic Pharmaceuticals President Named Health Care Hero Finalist in Atlanta Business Chronicle for Drug Abuse Deterrent Technology 2Rhythm Announces Study Demonstrating High Prevalence of Diabetic Gastroparesis Symptoms in the U.S. 2Rhythm Announces Study Demonstrating High Prevalence of Diabetic Gastroparesis Symptoms in the U.S. 3Rhythm Announces Study Demonstrating High Prevalence of Diabetic Gastroparesis Symptoms in the U.S. 4
... This May, Joao Pedras-Vasconcelos, Visiting Associate, Therapeutic ... European industry experts at Pharma IQ,s to discuss FDA ... Over the last two years, the regulations have been ... there has been some confusion within the industry as ...
... 2011 Morphotek®, Inc., a subsidiary of Eisai ... assets relating to a proprietary tumor targeting platform ... payment and future development milestones. TMI, a biotechnology ... the tumor-targeting peptide (TTP) platform capable of delivering ...
Cached Medicine Technology:FDA to Address Industry Questions About Biosimilar Regulations at the Pharma's IQ Immunogenicity Event 2Morphotek®, Inc. Announces Acquisition of Tumor Targeting Assets From Transmolecular, Inc. 2Morphotek®, Inc. Announces Acquisition of Tumor Targeting Assets From Transmolecular, Inc. 3
(Date:5/20/2013)... Lansing, MI (PRWEB) May 20, ... Michigan Lupus Foundation will be ... meeting in Lansing on June ... Monday, June 10th, 6:30 p.m. ... Professional Building (Across from Sparrow ...
(Date:5/20/2013)... (PRWEB) May 20, 2013 Co-founder of ... will be a keynote speaker at the 5th International ... The conference brings together company representatives and independent ... trends in Internet marketing and investments. , The 2013 ... Inn Business Hotel México from May 20 to 21. ...
(Date:5/20/2013)... (PRWEB) May 20, 2013 The ... and community leaders behind bars for good at an ... 22 beginning at 9 a.m. , More than ... Executive Lock-Up to benefit individuals and families affected by ... including city officials, local celebrities, realtors, doctors, attorneys, bankers, ...
(Date:5/20/2013)... May 20, 2013 ... Who:    Sloan Gibson, President, USO and CEO ... of Outreach Initiatives and Partners, Sesame ... , Representatives from:,              ... • U.S. House ...
(Date:5/20/2013)... 20, 2013 National law firm Parker Waichman ... Law Firm P.A., both based in Little Rock, Arkansas – ... proposed $7.25 billion settlement of a price-fixing case against Visa ... was filed Wednesday, May 15, 2013, in the U.S. District ... lawsuit against Visa and MasterCard (Case No. 1:05-md-1720) is titled ...
Breaking Medicine News(10 mins):Health News:EverSpark CEO to be Keynote Speaker at 5th International INVEST Domaining & Internet Marketing Conference in Mexico City 2Health News:MDA to Put Fort Lauderdale Community Leaders Behind Bars for Good 2Health News:USO to Celebrate Five-Year Partnership of Sesame Street/USO Experience for Military Families at Biannual Care Package Service Project on Capitol Hill 2Health News:USO to Celebrate Five-Year Partnership of Sesame Street/USO Experience for Military Families at Biannual Care Package Service Project on Capitol Hill 3Health News:USO to Celebrate Five-Year Partnership of Sesame Street/USO Experience for Military Families at Biannual Care Package Service Project on Capitol Hill 4Health News:Parker Waichman LLP Takes on the Credit Card Companies, Fights for Smaller Retailers that Form the U.S. Economy’s ‘Backbone’ 2Health News:Parker Waichman LLP Takes on the Credit Card Companies, Fights for Smaller Retailers that Form the U.S. Economy’s ‘Backbone’ 3
... in the open access journal BMC Medicine has found that ... people in India are flawed and the actual number of ... who are from the Administrative Staff College of India, conducted ... of Medical Sciences in Hyderabad. ,According to ...
... to be merry, for Christmas is fast approaching. The Santa ... celebration, spreading cheer// all around, are observed to be grossly ... ,Doctors in Scotland have explained how most of the ... frightfully fat, and need to diet on a war footing. ...
... spiritual leader Sri Sri Ravi Shankar will set up ... an "amalgamation of science and spirituality". ,Yezdi Batliwala ... Trust, the educational wing of the Art of Living ... Tripathy, the secretary of the state's higher education department, ...
... from Quebec had a man made heart implanted inside ... who does not have a heart beat! ,“Heartmate II”, ... Cecere and Dr Nadia Giannetti in a three-hour surgery on Nov. ... decade. It works using a turbine balanced within a magnetic field. ...
... most often end up selling their homes according to a ... ,People diagnosed with cancer experience loss of income, ... at the same time face a number of extra costs, ... ,The Macmillan Cancer Support research indicated that almost 20% ...
... problems are not protected from attacks or stroke by taking ... ,Folic acid or folate is one of the B ... Some medical practitioners prescribe it to prevent cardiac problems. ... Public Health and Tropical Medicine, New Orleans led a research ...
Cached Medicine News:
XL STABI Hydrophilic Acrylic Lens....
XL OCTO Hydrophilic Acrylic Lens....
One piece multifocal acrylic intraocular lens....
MemoryLens Prefolded Acrylic Lens....
Medicine Products: